Puma Biotech CFO granted stock, options

Puma Biotechnology, Inc. reported that its Chief Financial Officer, Maximo F. Nougues, received new equity awards on February 18, 2026.

Rhea-AI Filing Summary

Puma Biotechnology, Inc. reported that its Chief Financial Officer, Maximo F. Nougues, received new equity awards on February 18, 2026. He was granted a stock option for 66,541 shares at an exercise price of $0.00 per share and 46,739 Restricted Stock Units (RSUs) representing shares of common stock.

According to the award terms, both the RSUs and the option vest in four equal installments: one-fourth on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, in each case conditioned on his continued service with the company through the applicable vesting date.

Insider Trade Summary

Grant/Award: 113,280 shares

Grant/Award 2 txns

Insider NOUGUES MAXIMO F

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	66,541	$0.00	$0.00
Grant/Award	Common Stock	46,739	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 66,541 contracts (Direct); Common Stock — 240,023 shares (Direct)

Footnotes (2)

1. F1. Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.
2. F2. Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

FAQ

What equity awards did Puma Biotechnology (PBYI) CFO receive in this Form 4?

The CFO received a stock option for 66,541 shares and 46,739 Restricted Stock Units (RSUs). These awards relate to Puma Biotechnology common stock and reflect equity-based compensation rather than open-market purchases or sales.

How do the RSUs granted to Puma Biotechnology (PBYI) CFO vest?

The 46,739 RSUs vest in four equal installments. One-fourth vests on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, subject to the CFO’s continued service with Puma Biotechnology through each vesting date.

What is the vesting schedule for the Puma Biotechnology (PBYI) CFO stock option?

The 66,541-share stock option vests and becomes exercisable in four equal parts. One-fourth vests on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, contingent on the CFO remaining in service through each vesting date.

Did the Puma Biotechnology (PBYI) CFO buy or sell shares on the market in this Form 4?

No market purchases or sales are reported. The Form 4 shows equity grants: a 66,541-share stock option and 46,739 RSUs, both awarded as compensation with a vesting schedule tied to ongoing service at Puma Biotechnology.

What is the total Puma Biotechnology (PBYI) common stock reported as owned by the CFO after these transactions?

After the RSU grant, the Form 4 reports 240,023 shares of common stock beneficially owned. This figure reflects the CFO’s direct holdings as reported following the February 18, 2026 award transaction.

Are the Puma Biotechnology (PBYI) CFO’s equity awards subject to continued employment conditions?

Yes. Both the RSUs and stock options vest in four stages, each conditioned on the CFO’s continued service with Puma Biotechnology through July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 08:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NOUGUES MAXIMO F

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 1700

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		A		46,739(1)	A	$0(1)	240,023	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.68	02/18/2026		A		66,541		(2)	02/17/2036	Common Stock	66,541	$0	66,541	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

2. Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

	/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.